Literature DB >> 20870364

[Evolution of adherence to guidelines for prevention of group B streptococcal infections].

M Cortet1, C Dupont, V Prunaret-Julien, M-P Fernandez, E Peigne, C Huissoud, R-C Rudigoz.   

Abstract

OBJECTIVE: Assess the evolution in implementation of neonatal group B streptococcal infections prevention program in the Aurore network, between 2004 and 2009. PATIENTS AND METHODS: A cross-sectional study was conducted during one week in the whole maternity units of the Aurore network about implementation of the neonatal streptococcal infection prevention program. Deliveries occurring after 37 weeks of gestation were included. Every stage required by the prevention program was registered for every delivery. Results obtained during this study were compared with those obtained in 2004.
RESULTS: Seven hundred and forty-four patients were included in 2004 and 618 in 2009. Vaginal swab rate was 96.3% in 2009 and 91.1% in 2004 (P<0.001), with a positive rate of 10.2 and 14.2%, respectively (P=0.041). Antibiotic infusion rates during delivery did not increase significantly. Clinical and biological surveillance of exposed newborns was significantly increased (P<0.001). No neonatal infection was observed during the study among newborns included in the program.
CONCLUSION: Sensitization of caregivers about neonatal streptococcal infection prevention seems to be efficient to increase the application of the prevention program written by the Aurore network.
Copyright © 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20870364     DOI: 10.1016/j.jgyn.2010.07.008

Source DB:  PubMed          Journal:  J Gynecol Obstet Biol Reprod (Paris)        ISSN: 0150-9918


  1 in total

1.  Comparison of pre- and intrapartum screening of group B streptococci and adherence to screening guidelines: a cohort study.

Authors:  Mirjam Kunze; Katharina Zumstein; Filiz Markfeld-Erol; Roland Elling; Fabian Lander; Heinrich Prömpeler; Reinhard Berner; Markus Hufnagel
Journal:  Eur J Pediatr       Date:  2015-04-30       Impact factor: 3.183

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.